Manufactured by Schwarz Bioscience of Research Triangle Park, N.C. - Neupro® (rotigotine transdermal system), a skin patch designed to treat symptoms of early Parkinson's disease – has been approved by the USFDA.
Neupro - the first transdermal patch approved for the treatment of symptoms of Parkinson's disease – contains the drug rotigotine (not previously approved in the U.S.) is a member of the dopamine agonist class of drugs and is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours.
Schwarz Bioscience is the U.S. Subsidiary of Schwarz Pharma AG of Monheim, Germany.
Read the full report.
Comment Preview